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Electrophilic fluorinations of lithiated bis-lactim ethers
derived from cyclo-[L-AP4-D-Val] allow a direct access to a-
monofluorinated phosphonate mimetics of naturally occur-
ring phosphoserine and phosphothreonine, in enantiomer-
ically pure form and suitably protected for solid-phase
peptide synthesis.
Protein phosphatases play significant roles in signal transduc-
tion pathways pertaining to such diverse functions as gene
expression, growth, glycogen synthesis, immune activation and
neurotransmission. Most of the protein dephosphorylation
events occurring in the cell appear to be mediated by serine/
threonine-specific phosphatases (PPs), which are characterized
by using a metal dyad as the key component of catalysis.
Although varying in nature from one PPs to another, the
dinuclear metal ion center has been proposed to bind the
phosphate oxoanions and activate a water molecule for direct
hydrolysis of a phosphoester bond, while general acid catalysis
is accomplished by a conserved residue in the active site which
protonates the leaving group.1
The importance of PPs for cell physiology has made them
prominent targets for inhibitor design.2 Starting from the amino
acid sequences of endogenous phosphoproteins or small
phosphopeptides preferred as substrates, selective phosphatase
inhibitors have been designed. Non-hydrolizable mimetics of
such phosphopeptides have been prepared by replacement of the
phosphate ester oxygen by a methylene linkage, giving rise to
phosphonopeptide analogues. Nevertheless, phosphonate ana-
logues have shown lower affinity than the corresponding
phosphate esters for the enzymes that bind or hydrolyse
phosphorylated biomolecules. This loss of biological activity
may be attributable to the higher steric requirements and lower
electronegativity of the methylene group with respect to the
oxygen. A commonly used strategy for increasing the binding
potency of phosphonic acids has relied on the substitution of the
methylene hydrogens at the a position by fluorine atoms,3 thus
increasing the acidity of the phosphonate and reintroducing the
possibility of hydrogen-bonding interactions. Based on the pKa
values for the second deprotonation and the calculated electro-
static profiles, the a-monofluorinated phosphonates have been
proposed to match the properties of the phosphates they are
designed to mimic more closely than the a,a-difluorinated
ones.4 In recent years the performance of non-fluorinated, a-
monofluorinated and a,a-difluorinated phosphonate inhibitors
has been evaluated for several enzyme systems. Different
responses have been obtained for the series, revealing the
convenience of performing a complete “fluorinated phospho-
nate scan” when optimizing the binding to a targeted active
site.5
Methodologies for the synthesis of enantiomerically pure
(2S)-2-amino-4,4-difluoro-4-phosphonobutanoic acids, suita-
bly protected for their incorporation into peptides as mimetics
of L-phosphoserine (pSer) and L-phosphothreonine (pThr), have
been recently developed by Berkowitz and Otaka by using
difluoromethylphosphonate carbanions for the C–CF2P bond
formation.6 Despite its potential advantages, the corresponding
a-monofluorinated phosphonate mimetics have received little
attention. To the best of our knowledge, strategies for the
synthesis of the a-monofluorinated phosphonate mimetic of
pThr are not available in the literature, while only one
methodology has been reported for the preparation of the a-
monofluorinated phosphonate mimetic of pSer (FPab). Al-
though practical for the incorporation of FPab into phosphopep-
tide mimetics, the available synthetic route relies on a
non-selective hydrogenation of a fluorovinylphosphonate pre-
cursor, and gives rise to the 2-amino-4-fluoro-4-phosphonobu-
tanoic acid derivatives as diastereomeric mixtures which were
speculatively assigned the biological configuration based on
enzymatic digestion methods.7
In this area, we have shown that conjugate additions of
lithiated Schöllkopf’s bis-lactim ethers to vinylphosphonates
enable the stereocontrolled preparation of bis-lactim ethers
derived from 2-amino-4-phosphonobutanoic acid (AP4),8 that
have been efficiently transformed into optically pure phospho-
nate mimetics of pSer and pThr.9 More recently, we have found
that electrophilic substitutions on the bis-lactim ether derived
from cyclo-[L-AP4-D-Val] take place regio- and stereose-
lectively, and allow a direct access to a variety of 4-substituted
AP4 derivatives in enantiomerically pure form.10 In addition,
the electrophilic fluorination using the ‘N–F’ reagents has
become a valuable method for the selective fluorination of
activated aromatics, alkenes, and enolates.11 Moreover, using
N-fluorobenzenesulfonimide (NFSi) Differding has reported
the successful fluorination of a variety of carbanions stabilized
by a phosphonate ester group.12
Based on these precedents we envisaged the electrophilic
fluorinations of the Schöllkopfs´ bis-lactim ethers 3a,b as a
direct route for the synthesis of the a-monofluorinated phospho-
nate analogues of naturally occurring pSer 1,2a and pThr 1,2b
(see Scheme 1), in enantiomerically pure form and using a N-
Fmoc/O-ethyl phosphonic ester protection strategy for solid-
phase peptide synthesis.
Toward this end, slow addition of bis-lactim ether 3a‡ to a
solution of 2 equiv. of LDA in THF at 278 °C was followed 15
min later by the dropwise addition of NFSi. Reaction took place
rapidly, and after quenching with acetic acid and work-up,
mixtures of the 2A-fluorinated bis-lactims were isolated in a
combined yield of 72%, along with 10% of unreacted starting
material. Integration of the 1H decoupled 31P NMR spectrum of
† Electronic supplementary information (ESI) available: experimental data.
See http://www.rsc.org/suppdata/cc/b2/b204093j/ Scheme 1 a, R = H; b, R = Me.
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the crude reaction mixture revealed a 8.2+2.7+1.0 ratio for
4a+5a+6a (see Scheme 2). The use of 2 equiv. of NFSi resulted
in the complete reaction of 3a and a reduced ratio of mono- to
difluorination (4+3 instead of 11+1) with neither change in the
combined yield nor the level of 2,2A-syn stereoselectivity. When
LDA was added to the preformed equimolar mixture of 3a and
NFSi a 65% conversion to the desired monofluorinated products
4a+5a was achieved. As the difluorination was completely
suppressed in this case, the yield of 4a+5a could be increased to
78% by resubjecting the recovered material to these fluorination
conditions. Starting with the bis-lactim ether 3b,8 treatment
with LDA and subsequent reaction with NFSi afforded the
corresponding mixture of mono- and difluorinated products
4b+5b+6b, in a 7+7+1 ratio and 75% total yield. Thus, although
completely regioselective at position 2A, monofluorination was
not stereoselective in this case.§
Conversion of the monofluorinated bis-lactims 4–5a,b into
the desired pSer and pThr mimetics was straightforward. Mild
acid hydrolysis of the bis-lactim afforded the aminoesters 7a,b
and 9a,b, which were subsequently hydrolysed to the corre-
sponding amino acids 8a and 10a,b by treatment with lithium
hydroxide. Finally, Fmoc-protection under standard conditions
gave 1a and 2a,b in excellent yields.
Since none of the synthesized compounds provided crystals
suitable for X-ray diffraction analysis, the oxaphosphorinanes
13a,b were sought as suitable cyclic derivatives which would
enable assignment of the relative configurations by NMR
spectroscopy (see Scheme 3).
As expected, after protection of the amino group, chemo-
selective reduction of the carboxylic ester of 11a and 11b with
LiBH4 took place with simultaneous cyclization to the corre-
sponding N-Boc-aminooxaphosphorinanes 12a and 12b.
Finally, cleavage of the protecting groups by treatment with
TMSBr yielded 13a and 13b in good yields. Both compounds
showed in their 1H NMR spectra a pattern of signals suitable for
their stereochemical study by NOE difference spectroscopy.
Analyses of the sets of observed NOEs allowed to conclude a cis
1,3-diaxial relationship between the fluoro and the amino group
across the oxaphosphorinanes 13a and 13b. Stereochemical
assignments for 13a were eventually confirmed by an X-ray
crystal structure analysis.¶
In conclusion, electrophilic fluorinations of readily available
lithiated bis-lactim ethers derived from cyclo-[L-AP4-D-Val]
using commercial NFSi allow a direct access to a-mono-
fluorinated phosphonate mimetics of naturally occurring pSer
and pThr, in optically pure form and suitable protected for solid-
phase peptide synthesis, which may be useful for the prepara-
tion of inhibitors directed to serine/threonine-specific protein
phosphatases.
This work was supported by the Xunta de Galicia
(PDGIT00PXI10305PR) and the Ministerio de Ciencia y
Tecnología (BQU2000-0236). The authors thank Dr M. A.
Maestro for resolving the X-ray structure.
Notes and references
‡ 3a was prepared as described ,9 but using a O,O-diethyl vinylphosphonate
ester instead of a O,O-diallyl one.
§ Evidence supporting their relative configurations was obtained from
NMR analyses. Thus, for compounds 4–6a,b H-5 resonance appears
between 3.87 and 3.97 ppm, as a triplet with 5JH2H5 close to 3.5 Hz, typical
for a trans relation of substituents at the pyrazine ring.
¶ Crystal data for 13a: C4H9FNO3P, M = 169.09, orthorhombic, a =
6.7943(13), b = 8.718(3), c = 11.059(4) Å, U = 655.1(3) Å3, T = 298(2)
K, space group P212121, Z = 4, m(Mo-Ka) = 0.385 mm21, 3608 reflections
measured, 1612 unique (Rint = 0.0234) which were used in all calculations.
The final wR(F2) was 0.0627 (all data). Absolute structure (Flack)
parameter = 0.02(10). CCDC 185051. See http://www.rsc.org/suppdata/cc/
b2/b204093j/ for crystallographic data in .cif format.
1 M. D. Jackson and J. M. Denu, Chem. Rev., 2001, 101, 2313.
2 A. McCluskey, A. T. R. Sim and J. A. Sakoff, J. Med. Chem., 2002, 45,
1151.
3 G. M. Blackburn, D. Brown, S. J. Martin and M. J. Parratt, J. Chem.
Soc., Perkin Trans. 1, 1987, 181.
4 D. O’Hagan and H. S. Rzepa, Chem. Commun., 1997, 645.
5 D. B. Berkowitz, M. B. Bose, T. J. Pfannenstiel and T. Doukov, J. Org.
Chem., 2000, 65, 4498; J. Nieschalk, A. S. Batsanov, D. O’Hagan and
J. A. K. Howard, Tetrahedron, 1996, 52, 165; T. R. Burke, M. S. Smyth,
A. Otaka, M. Nomizu, P. R. Roller, G. Wolf, R. Case and S. E. Shoelson,
Biochemistry, 1994, 33, 6490.
6 A. Otaka, E. Mitsuyama, T. Kinoshita, H. Tamamura and N. Fujii, J.
Org. Chem., 2000, 65, 4888;  Berkowitz, D. B., MJ Eggen, Q. Shen and
R. K. Shoemaker, J. Org. Chem., 1996, 61, 4666.
7 A. Otaka, E. Mitsuyama, H. Watanabe, H. Tamamura and N. Fujii,
Chem. Commun., 2000, 1081.
8 V. Ojea, M. Ruiz, G. Shapiro and E. Pombo-Villar, J. Org. Chem., 2000,
65, 1984.
9 M. Ruiz, V. Ojea, G. Shapiro, H.-P. Weber and E. Pombo-Villar,
Tetrahedron Lett., 1994, 35, 4551; G. Shapiro, D. Buechler, V. Ojea, E.
Pombo-Villar, M. Ruiz and H.-P. Weber, Tetrahedron Lett., 1993, 34,
6255.
10 M. C. Fernández, J. M. Quintela, M. Ruiz and V. Ojea, Tetrahedron:
Asymmetry, 2002, 13, 233.
11 S. D. Taylor, C. C. Kotoris and G. Hum, Tetrahedron, 1999, 55,
12431.
12 E. Differding, R. O. Duthaler, A. Krieger, G. M. Rüegg and C. Schmit,
Synlett, 1991, 395.
Scheme 2 Reagents and conditions: (i) LDA (2 equiv.), THF, 278 °C, 15
min; (ii) NFSi, THF, 278 °C, 5 min; (iii) AcOH, 278 °C to rt; (iv) 0.25 M
HCl , THF, rt, 1–15 h; (v) LiOH, H2O, rt, 30 min; (vi) Fmoc-O-N-
succinimide, NaHCO3, acetone/H2O 1+1, rt, 14 h. a, R = H; b, R = Me.
Scheme 3 Reagents and conditions: (i) (Boc)2O, dioxane/H2O, rt, 2–7 h; (ii)
LiBH4, THF, 0–25 °C, 8 h; (iii) a: TMSBr, THF, 0–25 °C, 17 h; b: MeOH,
rt. a, R = H; b, R = Me.
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